Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
Esophageal Strictures-II: Clinical Features and Management01:26

Esophageal Strictures-II: Clinical Features and Management

Patients with esophageal strictures often experience a range of symptoms. Initially, they may have difficulty swallowing solid foods, which can progress to include liquids. Additional symptoms may involve chest pain or discomfort, regurgitating food and fluids, heartburn, unintentional weight loss, coughing or choking during meals, and hoarseness.
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Esophageal Achalasia01:27

Esophageal Achalasia

Esophageal achalasia is a chronic neurogenic disorder characterized by impaired relaxation of the lower esophageal sphincter (LES) and absent or ineffective peristalsis in the distal esophagus. This leads to a functional obstruction without a physical blockage, despite significant disruption of esophageal motility.EtiologyAchalasia is caused by degeneration of the myenteric (Auerbach's) plexus, specifically the loss of inhibitory ganglion cells that produce vasoactive intestinal peptide (VIP)...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma.

HemaSphere·2026
Same author

CD8 T lymphocytes deploy embryonic cell cycle control mechanisms for rapid cell proliferation.

EMBO reports·2026
Same author

Staff Perspectives on Non-Routine Compression Therapy for Inpatients With Venous Leg Ulcers: A Qualitative Study.

International wound journal·2026
Same author

Central and Peripheral Alterations of Retinal and Choroidal Vasculature in Multiple Sclerosis: Insights from Multimodal Imaging.

Ophthalmology science·2026
Same author

Multicenter Clinical Comparison of the 10-Minute AMDI Fast PCR Mini Respiratory Panel and the Cepheid Xpert Xpress CoV-2/Flu/RSV plus.

The Journal of molecular diagnostics : JMD·2026
Same author

Development and Testing of VOICES-C: A Questionnaire for Assessing the Quality and Experiences of End-of-Life Care for Children and Their Families.

Journal of palliative care·2026
Same journal

'The little things count': delivering dignified care.

Nursing times·2018
Same journal

The heart of the hospital.

Nursing times·2018
Same journal

The nurse's role in caring for people with dementia.

Nursing times·2018
Same journal

Hepatitis C and the ongoing challenge of genotype 3.

Nursing times·2018
Same journal

Implementing change in older people's acute care.

Nursing times·2018
Same journal

A total health economy approach to revalidation.

Nursing times·2018
See all related articles

Related Experiment Video

Updated: May 20, 2026

Adapting Human Videofluoroscopic Swallow Study Methods to Detect and Characterize Dysphagia in Murine Disease Models
08:32

Adapting Human Videofluoroscopic Swallow Study Methods to Detect and Characterize Dysphagia in Murine Disease Models

Published on: March 1, 2015

Medication errors in patients with dysphagia.

Jennifer Kelly1, David Wright, John Wood

  • 1Queen Elizabeth Hospital King's Lynn Foundation Trust.

Nursing Times
|July 11, 2012
PubMed
Summary
This summary is machine-generated.

Patients with dysphagia experience significantly higher medicine administration errors (MAEs), with a rate of 21.1% compared to 5.9% for others. This highlights the critical need for enhanced safety protocols in medication management for individuals with swallowing difficulties.

More Related Videos

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

Related Experiment Videos

Last Updated: May 20, 2026

Adapting Human Videofluoroscopic Swallow Study Methods to Detect and Characterize Dysphagia in Murine Disease Models
08:32

Adapting Human Videofluoroscopic Swallow Study Methods to Detect and Characterize Dysphagia in Murine Disease Models

Published on: March 1, 2015

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

Area of Science:

  • Healthcare quality and safety
  • Clinical pharmacy practice
  • Patient safety research

Background:

  • Medication administration for patients with dysphagia presents significant challenges and is susceptible to errors.
  • Dysphagia, or difficulty swallowing, impacts a substantial number of patients in acute care settings.
  • Ensuring safe and effective medication delivery is paramount for patient outcomes.

Purpose of the Study:

  • To quantify the incidence of medicine administration errors (MAEs) in acute hospital settings specifically for patients with dysphagia.
  • To compare the MAE rate in dysphagia patients with that of non-dysphagia patients.
  • To identify areas for improvement in medication safety for vulnerable patient populations.

Main Methods:

  • Direct observation of 65 nurse-led medication administration rounds across four acute general hospitals.
  • Data collection focused on the preparation and administration of oral medications.
  • Inclusion of patients with and without dysphagia, as well as those with enteral feeding tubes.

Main Results:

  • Excluding time-related errors, the normalized frequency of MAEs was 21.1% for patients with dysphagia.
  • In contrast, the MAE rate for patients without dysphagia was 5.9%.
  • A statistically significant difference in MAE rates was observed between the two groups.

Conclusions:

  • Patients with dysphagia exhibit a substantially higher rate of medicine administration errors.
  • Increased vigilance and tailored strategies are essential during the prescribing, dispensing, and administration phases for this patient group.
  • Further research and implementation of targeted interventions are warranted to mitigate MAEs in dysphagia patients.